Patient Selection Criteria and Surgical Resection Considerations when Evaluating Patients with Previously-Treated Advanced Melanoma

Published on: June 21, 2024

AMTAGVI (lifileucel) is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.
View Resource